Kite’s Yescarta yields positive results in ZUMA-1 trial in refractory large B-cell lymphoma

This article was originally published here

These results included updated overall survival data from the pivotal phase 2 study after three years following a single infusion of Yescarta, as well as an analysis from

The post Kite’s Yescarta yields positive results in ZUMA-1 trial in refractory large B-cell lymphoma appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply